A Comparison of the Neuroprotective and Reactivating Efficacy of a Novel Bispyridinium Oxime K870 with Commonly Used Pralidoxime and the Oxime HI-6 in Tabun-Poisoned Rats

Jiří Kassa1,*, Jana Hatlapatková1, Jana Žďárová Karasová1, Vendula Hepnarová1, Filip Caisberger2, Jaroslav Pejchal1

ABSTRACT
Aim: The comparison of neuroprotective and central reactivating effects of the oxime K870 in combination with atropine with the efficacy of standard antidotal treatment in tabun-poisoned rats.

Methods: The neuroprotective effects of antidotal treatment were determined in rats poisoned with tabun at a sublethal dose using a functional observational battery 2 h and 24 h after tabun administration, the tabun-induced brain damage was investigated by the histopathological evaluation and central reactivating effects of oximes was evaluated by the determination of acetylcholinesterase activity in the brain using a standard spectrophotometric method.

Results: The central reactivating efficacy of a newly developed oxime K870 roughly corresponds to the central reactivating efficacy of pralidoxime while the ability of the oxime HI-6 to reactivate tabun-inhibited acetylcholinesterase in the brain was negligible. The ability of the oxime K870 to decrease tabun-induced acute neurotoxicity was slightly higher than that of pralidoxime and similar to the oxime HI-6. These results roughly correspond to the histopathological evaluation of tabun-induced brain damage.

Conclusion: The newly synthesized oxime K870 is not a suitable replacement for commonly used oximes in the antidotal treatment of acute tabun poisonings because its neuroprotective efficacy is only slightly higher or similar compared to studied currently used oximes.

KEYWORDS
tabun; acetylcholinesterase; neurotoxicity; functional observational battery; histopathology; oximes; rats

AUTHOR AFFILIATIONS
1 Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defense, Hradec Králové, Czech Republic
2 Neurology, University Hospital Hradec Králové, Hradec Králové, Czech Republic
* Corresponding author: Faculty of Military Health Sciences, Třeběšská 1575, 500 01 Hradec Králové, Czech Republic; e-mail: kassa@pmfhk.cz

Received: 16 March 2021
Accepted: 16 June 2021
Published online: 11 November 2021

Acta Medica (Hradec Králové) 2021; 64(3): 145–152
https://doi.org/10.14712/18059694.2021.25
© 2021 The Authors. This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
INTRODUCTION

Nerve agents including tabun are highly toxic organophosphorus compounds that were developed and stockpiled for use as chemical warfare agents (1). Their main toxic mechanism is based on their covalent binding to the active site of acetylcholinesterase (AChE, EC 3.1.1.7) resulting in AChE irreversible inhibition and development of cholinergic crisis. As some nerve agents including tabun easily penetrate through the blood-brain barrier (BBB), they can cause centrally mediated seizure activity that can rapidly progress to status epilepticus and contribute to profound brain damage (2–4).

Tabun (O-ethyl-N,N-dimethyl phosphoramidocyanidate) is one of the most resistant nerve agents. It differs from other highly toxic organophosphates by its chemical structure and by the fact that commonly used antidotes (atropine in combination with an oxime) are not able to sufficiently eliminate tabun-induced acute toxic effects. Its acute toxic effects are extraordinarily difficult to counteract because of the existence of a free electron pair located on amidic nitrogen that makes the nucleophilic attack of oximes almost impossible (5, 6).

Severe intoxication with tabun usually leads to centrally mediated seizure activity and contribute to brain damage that is associated with long-lasting neurological and psychological injuries (7, 8). Therefore, the ability of antidotes to counteract acute neurotoxic effects of tabun and prevent tabun-poisoned organisms from irreversible lesions in the brain is very important for the successful antitodal treatment of acute tabun poisonings (2). However, all commonly used oximes are not able to sufficiently reactivate tabun-inhibited AChE and, in addition, their central reactivating efficacy is generally very low due to their low penetration through BBB (9–11).

Therefore, the development of new oxime or non-oxime reactivators of tabun-inhibited AChE has been a long-standing goal for the treatment of tabun poisoning. For this purpose, a novel dichlorinated bispyridinium oxime K870 with a double bond in the linker: 4-carbamoyl-1-[(2E)-4-{3,5-dichloro-4-[(hydroxyimino)methyl]-pyridinium-1-yl]but-2-en-1-yl]pyridinium dibromide was synthesized to improve the efficacy of antitodal treatment in reactivating tabun-inhibited AChE and eliminating tabun-induced acute neurotoxic effects (12).

The aim of this study was to compare the potential neuroprotective and central reactivating effects of newly developed oxime K870 with the oxime HI-6 and pralidoxime in combination with an anticholinergic drug atropine in tabun-poisoned rats. The tabun-induced neurotoxic signs and symptoms were determined using a functional observational battery (FOB), the tabun-induced brain damage was investigated by the histopathological evaluation using hematoxylin–eosin staining.

MATERIAL AND METHODS

ANIMALS

Male Wistar albino rats (6-week-old, 240–270 g, VELAZ, Prague, Czech Republic) without genetic modification were kept in an accredited animal facility (22 ± 2°C and 50 ± 10% relative humidity, 12-h day-night cycle) and allowed access to standard food (VELAZ) and tap water ad libitum. Handling of the experimental animals was approved by the Ethics Committee of the Faculty of Military Health Sciences in Hradec Kralove (Czech Republic) and were conducted in accordance with the Animal Protection Law and Animal Protection Regulations.

CHEMICALS

Tabun was obtained from the Technical Institute in Brno (Czech Republic) and was 90% pure. Its purity was asayed by acidimetric titration. The basic solution of tabun (1mg/1mL) was prepared in propylene glycol three days before starting the experiments. Actual solution of tabun was prepared from its basic solution with the help of saline immediately before its administration. Two oximes (pralidoxime, HI-6) were synthesized at the Department of Toxicology and Military Pharmacy of the Faculty of Military Health Sciences (University of Defence, Hradec Kralove, Czech Republic), the oxime K870 was synthesized at the Department of Chemistry of the Faculty of Science (University of Hradec Kralove, Czech Republic). Their purity was analyzed using HPLC technique with UV detection (310 nm) and they were more than 96% pure (13). All other drugs and chemicals of analytical grade were obtained commercially (Sigma-Aldrich, St. Louis, MO, USA) and used without further purification. The saline solution (0.9% NaCl, B Braun Melsungen AG, Melsungen, Germany) was used as a vehicle.

IN VIVO EXPERIMENTS

Animals were randomly divided into 6 groups (8 rats each): 1) a control group (administered with saline), 2) tabun-poisoned group ((220 µg/kg – 95% LD₅₀), 3) tabun-poisoned group treated with atropine sulphate alone (10 mg/kg), 4) tabun-poisoned group treated with atropine sulphate and K870 (100 mg/kg), 5) tabun-poisoned group treated with atropine sulphate and pralidoxime (197 mg/kg), 6) tabun-poisoned group treated with atropine sulphate and HI-6 (81 mg/kg).

Tabun was administered intramuscularly (i.m.) at a sublethal dose (220 µg/kg – 95% LD₅₀). One minute following tabun poisoning, the rats were treated i.m. with atropine (10 mg/kg b.w.) alone or in combination with the oxime HI-6 (81 mg/kg), pralidoxime (197 mg/kg) or K870 (100 mg/kg) at maximal tolerated doses (MTD, unpublished observations). All substances were administered intramuscularly (i. m.) at a volume of 1 mL/kg body weight (b.w.).

The neurotoxicity of tabun was monitored using FOB at 2 and 24 h following tabun poisoning. The evaluated markers of tabun-induced neurotoxicity in experimental animals were compared with the parameters obtained from control rats given saline instead of tabun and antidotes at the same volume (1 mL/kg b.w.). FOB consists of 42 measurements of sensory, motor and autonomic nervous functions. Some of them are scored (14), the others are measured in absolute units. The description of this method including statistical analysis has been already published (14, 15).
MEASUREMENT OF ACHE ACTIVITY IN THE BRAIN
To evaluate the reactivating efficacy of the oximes in the brain, the rats were decapitated after FOB test (24 h 30 min after intoxication), totally exsanguinated and the brain was rapidly removed, cut in half along the mid-sagittal plane and one half of the brain was immediately frozen at the temperature −70 °C. All experiments were performed in the same part of the day (from 08:00 h to 10:00 h). The spectrophotometric method of AChE activity determination and percentage of reactivation calculation including the statistical analysis was described previously (16, 17).

HEMATOXYLIN-EOSIN STAINING AND HISTOPATHOLOGY EVALUATION
To evaluate histopathological changes after tabun poisoning, second half of brain was fixed with a 10% neutral buffered formalin (Bamed s.r.o., Ceske Budejovic, Czech Republic). The description of sample preparation and the method of hematoxylin-eosin staining as well as histopathology evaluation including statistical analysis has been previously published (14, 18).

RESULTS
THE EVALUATION OF NEUROPROTECTIVE EFFICACY OF OXIMES STUDIED IN TABUN-POISONED RATS
The results of the experiments related to the measurement of tabun-induced neurotoxicity at 2 hours following tabun poisoning are divided into three parts (activity and neuromuscular measures, sensorimotor and excitability measures and autonomic measures) (15) and summarized in Table 1a–c. While five non-treated tabun-poisoned rats, two tabun-poisoned rats treated with atropine alone and one tabun-poisoned rat treated with atropine and pralidoxime died before the evaluation of tabun-induced neurotoxicity by FOB, all tabun-poisoned rats treated with atropine in combination with K870 or the oxime HI-6 survived till the end of experiment. The evaluation of tabun-induced neurotoxic signs and symptoms at 2 h following intoxication proved significant alteration of practically all observed parameters with the exception of urination, defecation and hindlimb grip strength (Table 1a–c). All types of antidotal treatment of tabun poisoning including atropine alone were able to prevent some tabun-induced signs of neurotoxicity observed at 2 h following tabun challenge.

Tab. 1a The values of tabun-induced activity and neuromuscular neurotoxic markers measured at 2 hours following tabun challenge by the functional observational battery (No 1–2, 4–14 – scored values, No 3, 15–18 – values in absolute units). Statistical significance: * p ≤ 0.05 (comparison with the control values). Applied abbreviations: RRF, air righting reflex from back position; RRV, air righting reflex from vertical position; x/M, average or modus value; ± s, standard deviation; A, atropine; n, number of surviving animals.

| 2 hours | Controls | Tabun + A | Tabun + A + HI-6 | Tabun + A + K870 | Tabun + atropine | Tabun |
|---------|----------|-----------|-----------------|-----------------|-----------------|------|
| No      | Marker   | x/M -/+s  | x/M -/+s        | x/M -/+s        | x/M -/+s        | x/M -/+s |
| 1       | posture  | 1.00      | 3.00            | 3.00            | 3.00            | 3.00*  | 7.00* |
| 2       | muscular tonus | 0.00   | -1.00*          | 0.00            | 0.00            | 0.00   | -2.00* |
| 3       | rearing  | 10.13     | 6.73            | 0.38*           | 1.06            | 0.88*  | 2.63*  | 2.88  | 1.50*  | 2.00  | 0.25*  | 0.71  |
| 4       | hyperkinesis | 0.00   | 2.00*           | 2.00*           | 0.00            | 0.00   | 7.00*  |
| 5       | tremors  | 0.00      | 0.00            | 3.00*           | 0.00            | 0.00   | 5.00*  |
| 6       | clonic movements | 0.00 | 0.00           | 0.00            | 0.00            | 0.00   | 2.00*  |
| 7       | tonic movements | 0.00   | 0.00            | 0.00            | 0.00            | 0.00   | 5.00*  |
| 8       | gait     | 0.00      | 1.00*           | 0.00            | 0.00            | 1.00*  | 7.00*  |
| 9       | ataxia   | 0.00      | 1.00*           | 0.00            | 0.00            | 1.00*  | 2.00*  |
| 10      | paresis  | 0.00      | 0.00            | 0.00            | 0.00            | 0.00   | 2.00*  |
| 11      | mobility score | 1.00 | 1.00            | 1.00            | 1.00            | 1.00   | 4.00*  |
| 12      | activity | 4.00      | 3.00            | 3.00            | 4.00            | 4.00   | 1.00*  |
| 13      | RRF      | 1.00      | 2.00*           | 1.00            | 1.00            | 2.00*  | 7.00*  |
| 14      | RRV      | 1.00      | 2.00*           | 1.00            | 1.00            | 2.00*  | 4.00*  |
| 15      | landing foot splay (mm) | 9.70 | 1.61            | 5.73            | 3.97            | 7.05   | 3.09   | 8.76  | 1.88  | 8.34  | 1.20  | 2.63*  | 3.81  |
| 16      | forelimb grip strength (kg) | 5.89 | 1.29            | 5.13            | 3.56            | 8.11   | 3.63   | 6.76  | 0.70  | 6.33  | 1.44  | 2.21*  | 3.28  |
| 17      | hindlimb grip strength (kg) | 2.73 | 0.46            | 2.96            | 3.51            | 2.69   | 2.69   | 1.69  | 0.66  | 1.26  | 0.43  | 0.91   | 1.27  |
| 18      | grip strength of all limbs (kg) | 12.01 | 1.66           | 3.86*           | 3.72            | 10.50  | 4.91   | 12.05 | 1.08  | 9.55* | 1.17  | 4.18*  | 3.40  |

n = 8 n = 7 n = 8 n = 8 n = 6 n = 3
with the exception of a decrease in rearing activity, alteration of righting reflex, slight impairment of gait, the absence of pupil response to light, a decrease in forelimb and hindlimb grip strength, decrease in body temperature and respiration difficulties (Table 1a–c). Miosis was changed to mydriasis due to the effect of atropine. The ability of K870 to protect tabun-poisoned rats from tabun-induced acute neurotoxicity was slightly higher compared to other oximes studied. Pralidoxime was not able to eliminate fur abnormalities, unprovoked activity (arousal), a decrease in muscular tonus, the alteration of righting reflex, impairment of gait, absence of approach and tail-pinch response, a decrease in grip strength of all limbs while the other oximes (HI-6, K870) were able to do that. In addition, the oxime HI-6 was not able to eliminate hyperkinesis and tremors while the oxime K870 was able to do that (Table 1a–c).

Tab. 1b The values of tabun-induced sensorimotor and excitability neurotoxic markers measured at 2 hours following tabun challenge by the functional observational battery (scored values). Statistical significance: * p ≤ 0.05 (comparison with the control values).

| 2 hours | Controls | Tabun + A + pralidoxime | Tabun + A + HI-6 | Tabun + A + K870 | Tabun + atropine | Tabun |
|---------|----------|------------------------|-----------------|-----------------|-----------------|-------|
| No      | Marker   | x/M ± s                | x/M ± s         | x/M ± s         | x/M ± s         | x/M ± s     |
| 1       | catch difficulty | 2.00 ± 0.00 | 2.00 ± 0.00 | 2.00 ± 0.00 | 2.00 ± 0.00 | 2.00 ± 0.00 | 1.00* |
| 2       | ease of handling  | 2.00 ± 0.00 | 2.00 ± 0.00 | 2.00 ± 0.00 | 2.00 ± 0.00 | 2.00 ± 0.00 | 1.00* |
| 3       | arousal (GSC)    | 1.00 ± 0.00 | 2.00* ± 0.00 | 1.00 ± 0.00 | 1.00 ± 0.00 | 1.00 ± 0.00 | 4.00* |
| 4       | tension          | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 | 2.00* |
| 5       | vocalisation     | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 | 3.00* |
| 6       | stereotypy       | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 | 5.00* |
| 7       | bizzare behavior | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 | 4.00* |
| 8       | approach response| 2.00 ± 0.00 | 1.00* ± 0.00 | 2.00 ± 0.00 | 2.00 ± 0.00 | 2.00 ± 0.00 | 1.00* |
| 9       | touch response   | 2.00 ± 0.00 | 2.00 ± 0.00 | 2.00 ± 0.00 | 2.00 ± 0.00 | 2.00 ± 0.00 | 1.00* |
| 10      | click response   | 2.00 ± 0.00 | 2.00 ± 0.00 | 2.00 ± 0.00 | 2.00 ± 0.00 | 2.00 ± 0.00 | 1.00* |
| 11      | tail-pinch response | 2.00 ± 0.00 | 1.00* ± 0.00 | 2.00 ± 0.00 | 2.00 ± 0.00 | 2.00 ± 0.00 | 1.00* |

n = 8 n = 7 n = 8 n = 8 n = 6 n = 3

Tab. 1c The values of tabun-induced autonomic neurotoxic markers measured at 2 hours following tabun challenge by the functional observational battery (No 1–7, 10–11, 13 – scored values, No 8–9, 12 – values in absolute units). Statistical significance: * p ≤ 0.05 (comparison with the control values).

| 2 hours | Controls | Tabun + A + pralidoxime | Tabun + A + HI-6 | Tabun + A + K870 | Tabun + atropine | Tabun |
|---------|----------|------------------------|-----------------|-----------------|-----------------|-------|
| No      | Marker   | x/M ± s                | x/M ± s         | x/M ± s         | x/M ± s         | x/M ± s     |
| 1       | lacrimation | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 | 4.00* |
| 2       | palpebral closure  | 1.00 ± 0.00 | 1.00 ± 0.00 | 1.00 ± 0.00 | 2.00* ± 0.00 | 1.00 ± 0.00 | 5.00* |
| 3       | endo/ exophtalmus | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 | 1.00* |
| 4       | fur abnormalities | 0.00 ± 0.00 | 7.00* ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 | 7.00* |
| 5       | skin abnormalities | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 | 4.00* |
| 6       | salivation      | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 | 2.00* |
| 7       | nose secretion  | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 | 3.00* |
| 8       | urination       | 2.25 ± 0.00 | 3.06 ± 0.00 | 6.25 ± 0.00 | 4.43 ± 0.00 | 3.13 ± 0.00 | 3.72 |
| 9       | defeation       | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 |
| 10      | pupil size      | 0.00 ± 0.00 | 2.00* ± 0.00 | 2.00* ± 0.00 | 1.00* ± 0.00 | 2.00* ± 0.00 | -2.00* |
| 11      | pupil response  | 1.00 ± 0.00 | 0.00* ± 0.00 | 0.00* ± 0.00 | 0.00* ± 0.00 | 0.00* ± 0.00 | -2.00* |
| 12      | body temperature (°C) | 37.50 ± 0.22 | 36.66* ± 1.47 | 36.42* ± 1.38 | 35.74* ± 0.37 | 35.94* ± 0.53 | 36.17* |
| 13      | respiration     | 0.00 ± 0.00 | -1.00* ± 0.00 | -1.00* ± 0.00 | 0.00 ± 0.00 | -1.00* ± 0.00 | -2.00* |

n = 8 n = 7 n = 8 n = 8 n = 6 n = 3
### Tab. 2a
The values of tabun-induced activity and neuromuscular neurotoxic markers measured at 24 hours following tabun challenge by the functional observational battery (No 1–2, 4–14 – scored values, No 3, 15–18 – values in absolute units). Statistical significance: * p ≤ 0.05 (comparison with the control values). Applied abbreviations: RRF, air righting reflex from back position; RRV, air righting reflex from vertical position; x/M, average or modus value; ± s, standard deviation; A, atropine; n, number of surviving animals.

| 24 hours | Controls | Tabun + A + pralidoxime | Tabun + A + HI-6 | Tabun + A + K870 | Tabun + Atr | Tabun |
|----------|-----------|--------------------------|------------------|------------------|-------------|-------|
| No | Marker | x/M | ± s | x/M | ± s | x/M | ± s | x/M | ± s | x/M | ± s | x/M | ± s |
| 1 | posture | 1.00 | | 1.00 | | 1.00 | | 1.00 | | 1.00 | | 1.00 | | 7.00* |
| 2 | muscular tonus | 0.00 | | 0.00 | | 0.00 | | 0.00 | | 0.00 | | 0.00 | | -2.00* |
| 3 | rearing | 0.75 | 0.71 | 3.25 | 2.76 | 3.38 | 6.32 | 0.63 | 1.06 | 3.88 | 7.61 | 0.25 | 0.46 |
| 4 | hyperkinesis | 0.00 | | 0.00 | | 0.00 | | 0.00 | | 0.00 | | 0.00 | | 3.00* |
| 5 | tremors | 0.00 | | 0.00 | | 0.00 | | 0.00 | | 0.00 | | 0.00 | | 5.00* |
| 6 | clonic movements | 0.00 | | 0.00 | | 0.00 | | 0.00 | | 0.00 | | 0.00 | | 2.00* |
| 7 | tonic movements | 0.00 | | 0.00 | | 0.00 | | 0.00 | | 0.00 | | 0.00 | | 5.00* |
| 8 | gait | 0.00 | | 0.00 | | 0.00 | | 0.00 | | 0.00 | | 1.00* | | 7.00* |
| 9 | ataxia | 0.00 | | 0.00 | | 0.00 | | 0.00 | | 0.00 | | 0.00 | | 2.00* |
| 10 | paresis | 0.00 | | 0.00 | | 0.00 | | 0.00 | | 0.00 | | 0.00 | | 2.00* |
| 11 | mobility score | 1.00 | | 1.00 | | 1.00 | | 1.00 | | 1.00 | | 1.00 | | 4.00* |
| 12 | activity | 4.00 | | 4.00 | | 3.00* | | 3.00* | | 2.00* | | 2.00* | | 1.00* |
| 13 | RRF | 1.00 | | 1.00 | | 1.00 | | 1.00 | | 1.00 | | 1.00 | | 7.00* |
| 14 | RRV | 1.00 | | 1.00 | | 1.00 | | 1.00 | | 1.00 | | 1.00 | | 4.00* |
| 15 | landing foot splay (mm) | 9.51 | 0.86 | 5.23* | 3.91 | 6.99* | 3.19 | 6.56* | 0.94 | 8.20 | 1.70 | 1.95* | 3.70 |
| 16 | forelimb grip strength (kg) | 6.34 | 1.27 | 6.63 | 4.30 | 8.61 | 5.64 | 8.24 | 1.35 | 7.31 | 1.32 | 1.89* | 3.72 |
| 17 | hindlimb grip strength (kg) | 3.14 | 1.32 | 1.91 | 1.32 | 2.10 | 1.17 | 1.84* | 0.39 | 2.25 | 0.91 | 0.53* | 0.99 |
| 18 | grip strength of all limbs (kg) | 11.23 | 0.97 | 10.41 | 6.67 | 10.80 | 4.74 | 10.09 | 1.34 | 12.04 | 1.37 | 2.76* | 5.19 |
| n | = 8 | = 6 | = 6 | = 6 | = 4 | = 2 |

### Tab. 2b
The values of tabun-induced sensorimotor and excitability neurotoxic markers measured at 24 hours following tabun challenge by the functional observational battery (scored values). Statistical significance: * p ≤ 0.05 (comparison with the control values).

| 24 hours | Controls | Tabun + A + pralidoxime | Tabun + A + HI-6 | Tabun + A + K870 | Tabun + Atr | Tabun |
|----------|-----------|--------------------------|------------------|------------------|-------------|-------|
| No | Marker | x/M | ± s | x/M | ± s | x/M | ± s | x/M | ± s | x/M | ± s | x/M | ± s |
| 1 | catch difficulty | 2.00 | | 2.00 | | 2.00 | | 2.00 | | 2.00 | | 1.00* |
| 2 | ease of handling | 2.00 | | 2.00 | | 3.00* | | 2.00 | | 2.00 | | 1.00* |
| 3 | arousal (GSC) | 1.00 | | 1.00 | | 1.00 | | 1.00 | | 2.00* | | 4.00* |
| 4 | tension | 0.00 | | 0.00 | | 0.00 | | 0.00 | | 0.00 | | 0.00 | | 2.00* |
| 5 | vocalisation | 0.00 | | 0.00 | | 0.00 | | 0.00 | | 0.00 | | 0.00 | | 3.00* |
| 6 | stereotypy | 0.00 | | 0.00 | | 0.00 | | 0.00 | | 0.00 | | 0.00 | | 5.00* |
| 7 | bizarre behavior | 0.00 | | 0.00 | | 0.00 | | 0.00 | | 0.00 | | 0.00 | | 5.00* |
| 8 | approach response | 1.00 | | 1.00 | | 1.00 | | 1.00 | | 1.00 | | 1.00 | | 1.00 |
| 9 | touch response | 2.00 | | 2.00 | | 2.00 | | 2.00 | | 2.00 | | 1.00* | | 1.00* |
| 10 | click response | 2.00 | | 2.00 | | 2.00 | | 2.00 | | 2.00 | | 2.00 | | 1.00* |
| 11 | tail-pincha response | 2.00 | | 1.00* | | 2.00 | | 2.00 | | 2.00 | | 2.00 | | 1.00* |
| n | = 8 | = 6 | = 6 | = 6 | = 4 | = 2 |
The results of the experiments related to the measurement of tabun-induced neurotoxicity at 24 hours following tabun poisoning are divided into three parts (activity and neuromuscular measures, sensorimotor and excitability measures and autonomic measures) (15) and summarized in Table 2a–c. Six non-treated tabun-poisoned rats, four tabun-poisoned rats treated with atropine alone and two tabun-poisoned rats treated with the oxime K870, HI-6 or pralidoxime in combination with atropine died before the evaluation of tabun-induced neurotoxicity by FOB. The evaluation of tabun-induced neurotoxic signs at 24 h following intoxication proved significant alteration of practically all observed parameters with the exception of rearing, urination, defecation and approach response (Table 2a–c).

All studied oximes in combination with atropine were able to prevent almost all tabun-induced signs of neurotoxicity observed at 24 h following tabun challenge with the exception of a slight decrease in activity, body temperature, landing foot splay and hindlimb grip strength. On the other hand, the ability of atropine alone to eliminate or at least reduce tabun-induced signs of acute neurotoxicity was lower compared to all oximes studied in combination with atropine. Atropine alone was not be able to eliminate hyperkinesis, tremors, slight impairment of gait in the form of ataxia, no reaction during a reflex testing consisting of recording each rat’s response to the touch of the pen to the posterior flank and a decrease in body temperature (Table 2a–c).

### Tab. 2c
The values of tabun-induced autonomic neurotoxic markers measured at 24 hours following tabun challenge by the functional observational battery (No 1–7, 10–11, 13 – scored values, No 8–9, 12 – values in absolute units). Statistical significance: * p ≤ 0.05 (comparison with the control values).

| 24 hours | Controls | Tabun + A + pralidoxime | Tabun + A + HI-6 | Tabun + A + K870 | Tabun + atropine | Tabun |
|----------|----------|-------------------------|-----------------|-----------------|-----------------|-------|
| No       | Marker   | x/M −/+s | x/M −/+s | x/M −/+s | x/M −/+s | x/M −/+s |
| 1        | lacrimation | 0.00  | 0.00   | 0.00   | 0.00   | 0.00   | 4.00* |
| 2        | palpebral closure | 1.00  | 1.00   | 1.00   | 1.00   | 1.00   | 5.00* |
| 3        | endo/ exophtalmus | 0.00  | 0.00   | 0.00   | 0.00   | 0.00   | 1.00* |
| 4        | fur abnormalities | 0.00  | 0.00   | 0.00   | 0.00   | 0.00   | 7.00* |
| 5        | skin abnormalities | 0.00  | 0.00   | 0.00   | 0.00   | 0.00   | 4.00* |
| 6        | salivation | 0.00  | 0.00   | 0.00   | 0.00   | 0.00   | 2.00* |
| 7        | nose secretion | 0.00  | 0.00   | 0.00   | 0.00   | 0.00   | 3.00* |
| 8        | urination | 0.00  | 0.00   | 0.00   | 0.00   | 0.00   | 0.00  |
| 9        | defeation | v0.00 | 0.00   | 0.00   | 1.00   | 0.00   | 0.00  |
| 10       | pupil size | 0.00  | 0.00   | 0.00   | 0.00   | 0.00   | −2.00* |
| 11       | pupil response | 1.00  | 1.00   | 1.00   | 1.00   | 1.00   | 0.00  |
| 12       | body temperature (°C) | 37.55 | 0.17   | 36.48* | 0.36   | 36.67  | 0.52  |
|          |           | 36.80  | 0.45   | 36.41* | 0.12   | 36.90* | 0.57  |
| 13       | respiration | 0.00  | 0.00   | 0.00   | 0.00   | −1.00* | −2.00* |
| n = 8    | n = 6    | n = 6   | n = 6   | n = 4   | n = 2   |

### Tab. 3
Percentage of reactivation of tabun-inhibited AChE by oximes in rat brain in vivo.

| TREATMENT                  | AChE activity (mkat/kg) |
|----------------------------|-------------------------|
| Brain                      |                         |
| Saline control             | 102.4 ± 2.44            |
| Atropine control           | 39.56 ± 10.97*          |
| Atropine + K870 (% reactivation) | 43.02 ± 10.91 (5.5) |
| Atropine + pralidoxime (% reactivation) | 42.17 ± 6.35 (4.2) |
| Atropine + HI-6 (% reactivation) | 31.18 ± 6.40 (0)      |

* Means ± S.E.M., n = 4–8.
* * % reactivation was determined using the AChE activity values: \{1 − (((saline control) − (oxime + atropine))/((saline control) − (atropine control)))\} × 100.
HISTOPATHOLOGICAL EVALUATION OF TABUN-INDUCED BRAIN DAMAGE

Significantly increased histopathological damage scores were only found in amygdaloid body ($p = 0.005$) of tabun-poisoned rats without treatment when compared to control animals. In this group, shrunken eosinophilic neurons were present, especially in basolateral and central nuclei of this brain region in 1 of 2 surviving animals. Administration of atropine alone or its mixture with K870, pralidoxime or HI-6 significantly reduced tabun-induced histopathological damage of amygdaloid body ($p = 0.016, 0.008, 0.008$, and $0.008$).

No other significant changes were observed.

DISCUSSION

Severe poisoning with nerve agents including tabun can cause long-term overstimulation of the central muscarinic receptors leading to increased glutamatergic activity and subsequent excitotoxic damage of the brain (19, 20). Therefore, the antidotes with sufficient neuroprotective efficacy are important for the successful antidotal treatment of acute tabun poisonings.

It was found that atropine alone is not able to prevent tabun-induced seizures and subsequent neurotoxic effects including the brain damage following sublethal or lethal poisoning with tabun due to its low central antimuscarinic activity (21, 22). Thus, atropine should be combined with AChE reactivator in the antidotal treatment of tabun poisonings to improve its neuroprotective efficacy. However, the ability of commonly used oximes to eliminate tabun-induced acute neurotoxic effects is insufficient because of low reactivation of tabun-inhibited AChE and limited penetration through BBB (2, 9, 23–26). Therefore, new oximes with higher potency to reactivate tabun-inhibited AChE and to counteract tabun-induced acute neurotoxicity are still searched in order to increase the efficacy of antidotal treatment of acute tabun poisonings. Unfortunately, the presently available database on reactivators presented in the past few years gives no indication of a candidate which is clearly superior to the classic oximes.

The design of newly developed oximes should respect not only the goal to increase their reactivating efficacy via higher affinity to AChE but also the goal to increase their BBB penetration as much as possible. It was demonstrated that proper length between covalently connected proper peripheral site ligand and a non-ionic part containing nucleophilic aldoxime in the structure of AChE resulted in higher reactivation potency (27). The oxime K870 (dichlorinated bispyridinium AChE reactivator) has been developed based on aforementioned approach (12, 28–30).

Our results demonstrate that the neuroprotective efficacy of studied oximes is comparable. At 2 h after tabun administration, the ability of the oxime K870 to eliminate tabun-induced neurotoxic signs and symptoms was slightly higher than the neuroprotective efficacy of pralidoxime and similar to the efficacy of the oxime HI-6. No significant differences among all three groups (atropine with one of the tested oxime) at 24 h after tabun poisoning were found, either. On the other hand, the neuroprotective efficacy of atropine alone was markedly lower compared to the combination of atropine with one of studied oximes, especially at 24 h after tabun poisoning. This finding corresponds to the literature data (21). The differences in the neuroprotective efficacy of studied oximes do not correspond to their reactivating efficacy in the brain. Although the ability of K870 to reactivate tabun-inhibited AChE was the highest, the potency of all oximes studied to reactivate tabun-inhibited brain AChE was generally very low. This finding is supported by the fact that at least two tabun-poisoned rats died within 24 h after tabun challenge in all experimental groups. As the neuroprotective efficacy of all oximes studied is not possible to explain by their central reactivating efficacy that was very small, their neuroprotective efficacy could be also caused by their direct pharmacological effects such as inhibition of acetylcholine release, interaction with presynaptic cholinergic nerve terminals and/or with postsynaptic receptors (31–33).

Above mentioned data roughly correlate with histopathological evaluation. In comparison with our previous study (14), histopathological picture of tabun-poisoned rats without antidotal treatment was scarce. Significant damage was only found in amygdaloid body, which represents nuclei susceptible to excitotoxic damage (19). Nevertheless, these results are highly affected by a very low number of surviving animals that underwent the assessment. Regarding treated tabun-poisoned rats, no statistically significant differences were observed among all experimental groups as in case of the evaluation of neuroprotective and reactivating efficacy of all oximes studied.

CONCLUSIONS

It was found that neuroprotective and central reactivating efficacy of K870 did not prevail the effectiveness of currently available oximes studied and, therefore, it is not a suitable replacement for commonly used oximes in the antidotal treatment of acute tabun poisonings. Thus, a new structured, stepwise approach and a comprehensive set of in vitro and in vivo studies are required for the successful identification and downselection of new candidate reactivators with better entering into the active site of AChE-tabun complex and higher penetration through BBB.

ACKNOWLEDGEMENTS

The study was funded by the Ministry of Defence of the Czech Republic – “Long-term organization development plan – Medical Aspects of Weapons of Mass Destruction” of the Faculty of Military Health Sciences Hradec Králové, University of Defence, Czech Republic.

REFERENCES

1. Black R. Development, historical use and properties of chemical warfare agents. In: Worek F, Jenner J, Thierman H, eds. Chemical Warfare Toxicology, Royal Society of Chemistry, Cambridge, 2016: 1–28.
2. Bajgar J. Organophosphate/nerve agent poisoning: mechanism of action, diagnosis, prophylaxis, and treatment. Adv Clin Chem 2004; 38: 151–216.
3. Colovic MB, Krstic DZ, Lazarevic-Pasti TD, Bondzic AM, Vasic VM. Acetylcholinesterase inhibitors: pharmacology and toxicology. Curr Neuropharmacol 2013; 11: 315–35.

4. Delfino RT, Ribeiro TS, Figueroa-Villar JD. Organophosphorus compounds as chemical warfare agents: a review. J Braz Chem Soc 2009; 20: 407–28.

5. Cabal J, Baigaj J. Tabun – reappearance 50 years later (in Czech).

6. Ekström F, Akfur C, Tunemalm AK, Lundberg S. Structural changes of phenylalanine 338 and histidine 447 revealed by the crystal structures of tabun-inhibited murine acetylcholinesterase. Biochemistry 2006; 45: 74–81.

7. Hoffmann A, Eisenkraft A, Finkelstein A, Schein O, Rotman E, Dushnitsky T. A decade after the Tokyo sarin attack: a review of neurological follow-up of the victims. Mil Med 2007; 172: 607–10.

8. Yamashita H, Abe O, Kasei K, et al. Human brain structural changes related to acute single exposure to sarin. Ann Neuro 2007; 61: 37–46.

9. Jokanovic M, Prostran M. Pyridinium oximes as cholinesterase reactivators. Structure-activity relationship and efficacy in the treatment of poisoning with organophosphorus compounds. Curr Med Chem 2009; 16: 2177–88.

10. Marrs TC, Rice P, Vale JA. The role of oximes in the treatment of nerve agent poisoning in civilian casualties. Toxicol Rev 2006; 25: 297–323.

11. Wilhelm CM, Snider TH, Babin MC, Jett DA, Platoff GE Jr, Yeung DT. The ICCP collaborative study on organophosphorus compounds as chemical warfare agents or pesticides. Toxicol Appl Pharmacol 2014; 281: 254–65.

12. Zorbaz T, Malinak D, Marakovic N, et al. Pyridinium oximes with ortho-positioned chlorine moiety exhibit improved physicochemical properties and efficient reactivation of human acetylcholinesterase inhibited by several nerve agents. J Med Chem 2018; 61: 10753–66.

13. Jun D, Kuca K, Stodulka P, et al. HPLC analysis of HI-6 dichloride and dimethanesulfonate – antidotes against nerve agents and organophosphorus pesticides. Anal Lett 2007; 40: 2783–7.

14. Kassa J, Misik J, Hatlapatkova J et al. The evaluation of the reactivating and neuroprotective efficacy of two newly prepared bispyridinium oximes (K305, K307) in tabun-poisoned rats – a comparison with trimedoxime and the oxime K203. Molecules 2017; 22: 1152.

15. Moser VC, Tilson H, McPhail RC et al. The IPCS collaborative study on neurobehavioral screening methods: II. Protocol design and testing procedures. NeuroToxicology 1997; 18: 929–38.

16. Ellman GL, Courtney DK, Andres VJ; Featherstone RM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961; 7: 88–93.

17. Clement JG, Hansen AS, Boulet CA. Efficacy of HLö-7 and pyridoxime as antidotes of nerve agent poisoning in mice. Arch Toxicol 1992; 66: 216–9.

18. Paxinos G, Watson C. The rat brain in stereotactic coordinates, 6th ed. Academic Press, San Diego, 2006: 307.

19. Chen Y. Organophosphate-induced brain damage: Mechanisms, neuropsychiatric and neurological consequences, and potential therapeutic strategies. NeuroToxicology 2012; 33: 391–600.

20. Shihi TM, Duniho SM, McDonough JH. Control of NA-induced seizures is critical for neuroprotection and survival. Toxicol Appl Pharmacol 2003; 188: 69–80.

21. Kassa J, Kunesová G. Comparison of the neuroprotective effects of the newly developed oximes (K027, K048) with trimedoxime in tabun-poisoned rats. J Appl Biomed 2006; 4: 123–34.

22. McDonough JH Jr, Zoefell LD, Monagle J, Copeland TL, Smith CD, Shih TM. Anticonvulsant treatment of nerve agent seizures: anticholinergics versus diazepem in soman-intoxicated guinea-pigs. Epilepsia Res 2000; 38: 1–14.

23. Jokanovic M. Structure-activity relationship and efficacy of pyridinium oximes in the treatment of poisoning with organophosphorus compounds: a review of recent data. Curr Top Med Chem 2012; 12: 1775–89.

24. Kassa J, Krejcova G. Neuroprotective effects of currently used antidotes in tabun poisoned rats. Pharmcol Toxicol 2003; 92: 258–64.

25. Worek F, Widmann R, Knopff O, Sznizicz L. Reactivating potency of obidoxime, pralidoxime, HI-6 and HLö-7 in human erythrocyte acetylcholinesterase inhibited by highly toxic organophosphorus compounds. Arch Toxicol 1998; 72: 237–43.

26. Zdarova Karasova J, Pohanka M, Musilek K, Zmek F, Kuca K. Passive diffusion of acetylcholinesterase oxime reactivators through the blood-brain barrier: Influence of molecular structure. Toxicol in Vitro 2010; 24: 1838–44.

27. de Koning MC, van Grol M, Noort D. Peripheral site ligand conjugation to a non quaternary oxime enhances reactivation of nerve agent-inhibited human acetylcholinesterase. Toxicol Lett 2011; 206: 54–9.

28. Masson P, Nachon F, Lockridge O. Structural approach to the aging of phosphorylated cholinesterases. Chem Biol Interact 2010; 187: 157–62.

29. Kuca K, Jun D, Musilek K. Structural requirements of acetylcholinesterase reactivators. Mini Rev Med Chem 2006; 6: 269–77.

30. Musilek K, Kuca K, Jun D, Doalezal M. Progress in synthesis of new acetylcholinesterase reactivators during the period 1990–2004. Curr Org Chem 2007; 11: 329–38.

31. Niessen KV, Tattersall JEH, Timperley CM, et al. Interaction of bispyridinium compounds with the orthosteric binding site of human a7 and Torpedo californica nicotinic acetylcholine receptors (nAChRs). Toxicol Lett 2011; 206: 100–4.

32. Sürig U, Gaal K, Kostenis E, Tränkle C, Mohr K, Holzgrabe U. Muscarinic allosteric modulators. Atypical structure-activity-relationship in bispyridinium-type compounds. Arch Pharm Chem Life Sci 2006; 339: 207–12.

33. Van Helden HPM, Busker RW, Melchers BPC, Brujinzeel PLB. Pharmacological effects of oximes: how relevant are they? Arch Toxicol 1996; 70: 779–86.